Key Points to Consider:
- Revelation Biosciences (REVB, Financial) is implementing a 1-for-3 reverse stock split.
- The company aims to meet Nasdaq's minimum bid price requirement.
- Analysts forecast a substantial upside potential of over 20,000%.
Revelation Biosciences (REVB) has announced a strategic 1-for-3 reverse stock split, scheduled for July 7, 2025. The primary goal of this maneuver is to elevate the market price per share, thereby aiding the company in adhering to Nasdaq's minimum bid price criteria. This move is crucial for sustaining its listing status and possibly attracting more investors.
Wall Street Analysts' Insights
According to projections from two seasoned analysts, the one-year price target for Revelation Biosciences Inc (REVB, Financial) averages at $170.73. This forecast ranges from a high of $320.00 to a low of $21.45. These estimates reveal an extraordinary potential upside of 20,720.12% from the current price point of $0.82. Investors seeking more detailed insights can explore further on the Revelation Biosciences Inc (REVB) Forecast page.
The brokerage firm's consensus rating for Revelation Biosciences Inc (REVB, Financial) stands at an average recommendation of 2.0. This "Outperform" status suggests that analysts expect the stock to perform well above the market average. The rating system operates on a scale from 1 to 5, where 1 signifies a Strong Buy and 5 implies a Sell.
